35,30 $
0,20 %vorgestern
Nasdaq, 1. März, 22:00 Uhr
ISIN
US45258J1025
Symbol
IMVT
Berichte

Immunovant Inc Aktie News

Neutral
GlobeNewsWire
20 Tage alt
NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal third quarter ended December 31, 2023.
Positiv
InvestorPlace
26 Tage alt
As 2023 wrapped up, Russell 2000 stocks, mirroring the dynamics of small-to-mid-cap companies, showed resilience, outperforming their initial stance. The iShares Russell 2000 ETF (NYSEARCA: IWM ), a key barometer for these stocks, boasts over $60 billion in assets and a robust daily trading volume surpassing 40 million, setting an impressive stage for these agile market players.
Positiv
InvestorPlace
etwa ein Monat alt
The beginning of earnings season is a good time to look at stocks that analysts are upgrading. For growth-oriented investors, that may mean looking at some of the top-rated Russell 2000 stocks.
Positiv
The Motley Fool
etwa 2 Monate alt
Biotech has been out of favor among investors for over two years. The sector could be on the verge of a trend reversal because of multiple tailwinds.
Positiv
Seeking Alpha
etwa 2 Monate alt
Chris DeMuth Jr. discusses his position in uranium and his belief that nuclear energy will play a significant role in the future of energy production. He also updates us on SHF Holdings, a fintech company serving the cannabis industry, and predicts its growth potential in the coming years.
Neutral
GlobeNewsWire
2 Monate alt
NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will provide a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 10:30 am ET.
Positiv
Investors Business Daily
2 Monate alt
Immunovant unveiled promising results for a Graves' disease treatment on Thursday, helping IMVT stock reverse a recent downfall.
Neutral
GlobeNewsWire
2 Monate alt
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves' disease meaningfully exceeded 50% response rates.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen